MedTrace Logo

Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery

NCT00654992 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2009-06-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether erythropoietin is effective in preventing acute kidney dysfunction after coronary artery bypass grafting surgery.

Conditions

  • Kidney Failure, Acute

Interventions

DRUG

Erythropoietin-Beta

300 IU/kg of EPO or saline intravenously before surgery

DRUG

Normal Saline

300 IU/kg of normal saline intravenously before surgery

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Principal Investigators

  • Ki Young, Na, MD PhD · Department of Internal Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-02-29
Completion
2009-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00654992 on ClinicalTrials.gov